Cancer Vaccine

The Wall Street Journal analysis notes that market expectations for Moderna and Merck’s cancer vaccine mRNA-4157 may exceed what the data supports. While the vaccine showed promise in reducing recurrence risk in melanoma trials, sample sizes remain limited and long-term efficacy is unverified. Analysts caution that mRNA technology applications in oncology are still in early stages, and investors should be wary of short-term price volatility. Editor: GoodInfo Global News Team ...

Pharmaceutical giants Merck and Moderna have announced breakthrough results from their jointly developed mRNA cancer vaccine, which demonstrates significant efficacy in preventing melanoma recurrence. This milestone marks a new era in personalized cancer treatment, offering renewed hope to millions of cancer patients worldwide.